Close

New drug for symptom control presented at symposium

Reading Time: < 1 minute Sharing information at the symposium is what it’s all about. Today, Randall Kaye, chief medical officer from Avanir Pharmaceuticals, chose the symposium to give a presentation on a newly approved FDA drug for emotional lability (uncontrollable laughter and crying) called Nueudexta. Emotional lability is a symptom that is experienced by some people living with MND. Nuedexta is actually…